• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Gemtuzumab ozogamicin: one size does not fit all--the case for personalized therapy.

作者信息

Ravandi Farhad

出版信息

J Clin Oncol. 2011 Feb 1;29(4):349-51. doi: 10.1200/JCO.2010.32.2693. Epub 2010 Dec 20.

DOI:10.1200/JCO.2010.32.2693
PMID:21172885
Abstract
摘要

相似文献

1
Gemtuzumab ozogamicin: one size does not fit all--the case for personalized therapy.
J Clin Oncol. 2011 Feb 1;29(4):349-51. doi: 10.1200/JCO.2010.32.2693. Epub 2010 Dec 20.
2
Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial.鉴定能够从吉妥珠单抗奥佐米星治疗中获益的急性髓细胞性白血病患者：MRC AML15 试验的结果。
J Clin Oncol. 2011 Feb 1;29(4):369-77. doi: 10.1200/JCO.2010.31.4310. Epub 2010 Dec 20.
3
[Gemtuzumab ozogamicin as monotherapy and combination therapy for acute myelogenous leukemia].
Rinsho Ketsueki. 2007 Jun;48(6):458-67.
4
Gemtuzumab ozogamicin plus cytarabine determines complete remission in acute myeloid leukemia refractory to a double conventional treatment: a case report.吉妥珠单抗奥唑米星联合阿糖胞苷使难治性急性髓系白血病在双重传统治疗后达到完全缓解：一例报告
Haematologica. 2004 Jun 1;89(6 Suppl):ECR18.
5
Improved outcome of patients with low- and intermediate-risk cytogenetics acute myeloid leukemia (AML) in first relapse with gemtuzumab and cytarabine versus cytarabine: results of a retrospective comparative study.低危和中危细胞遗传学急性髓细胞白血病（AML）患者在首次复发时使用吉妥珠单抗和阿糖胞苷与阿糖胞苷相比的结果：一项回顾性比较研究的结果。
Cancer. 2011 Mar 1;117(5):974-81. doi: 10.1002/cncr.25554. Epub 2010 Oct 18.
6
Gemtuzumab ozogamicin, mitoxantrone, and etoposide in newly diagnosed acute myeloid leukemia patients with persistent leukemia after a course of induction therapy.
Ann Hematol. 2011 Jun;90(6):733-5. doi: 10.1007/s00277-010-1076-0. Epub 2010 Sep 21.
7
Gemtuzumab ozogamicin plus cytarabine in elderly patients with relapsed or refractory acute myeloid leukaemia.吉妥珠单抗奥唑米星联合阿糖胞苷治疗复发或难治性急性髓系白血病老年患者
Br J Haematol. 2008 May;141(5):744-5. doi: 10.1111/j.1365-2141.2008.07096.x. Epub 2008 Mar 27.
8
Post-transplant maintenance therapy with azacitidine and gemtuzumab ozogamicin for high-risk acute myeloid leukaemia.阿扎胞苷和吉妥珠单抗奥唑米星用于高危急性髓性白血病的移植后维持治疗。
Br J Haematol. 2015 Jun;169(5):756-9. doi: 10.1111/bjh.13248. Epub 2014 Dec 17.
9
Pilot study of gemtuzumab ozogamicin (GO), fludarabine, cytarabine and idarubicin combined regimen (GO-FLAI) as first-line induction therapy plus GO alone as consolidation therapy for elderly acute myeloid leukemia patients.
Acta Haematol. 2007;118(1):7-9. doi: 10.1159/000100992. Epub 2007 Mar 26.
10
Molecular response in two children with relapsed acute myeloid leukemia treated with a combination of gemtuzumab ozogamicin and cytarabine.两名复发急性髓系白血病儿童接受吉妥珠单抗奥唑米星与阿糖胞苷联合治疗后的分子反应
Haematologica. 2006 Mar;91(3):419-21.

引用本文的文献

1
The impact of trisulfide modification of antibodies on the properties of antibody-drug conjugates manufactured using thiol chemistry.抗体的三硫化物修饰对使用硫醇化学方法制备的抗体-药物偶联物性质的影响。
MAbs. 2017 Apr;9(3):490-497. doi: 10.1080/19420862.2017.1285478. Epub 2017 Jan 31.
2
Frontline treatment of acute myeloid leukemia in adults.成人急性髓系白血病的一线治疗
Crit Rev Oncol Hematol. 2017 Feb;110:20-34. doi: 10.1016/j.critrevonc.2016.12.004. Epub 2016 Dec 11.
3
Ocular Adverse Events Associated with Antibody-Drug Conjugates in Human Clinical Trials.
人类临床试验中与抗体药物偶联物相关的眼部不良事件。
J Ocul Pharmacol Ther. 2015 Dec;31(10):589-604. doi: 10.1089/jop.2015.0064. Epub 2015 Nov 5.
4
Antibody-Drug Conjugates: Design, Formulation and Physicochemical Stability.抗体药物偶联物：设计、制剂与物理化学稳定性
Pharm Res. 2015 Nov;32(11):3541-71. doi: 10.1007/s11095-015-1704-4. Epub 2015 May 19.
5
Enediynes: Exploration of microbial genomics to discover new anticancer drug leads.烯二炔类：探索微生物基因组学以发现新的抗癌药物先导物。
Bioorg Med Chem Lett. 2015 Jan 1;25(1):9-15. doi: 10.1016/j.bmcl.2014.11.019. Epub 2014 Nov 14.
6
Site-specific antibody drug conjugates for cancer therapy.用于癌症治疗的靶向抗体药物偶联物。
MAbs. 2014 Jan-Feb;6(1):34-45. doi: 10.4161/mabs.27022.
7
Drug-conjugated antibodies for the treatment of cancer.用于癌症治疗的药物偶联抗体。
Br J Clin Pharmacol. 2013 Aug;76(2):248-62. doi: 10.1111/bcp.12044.
8
The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma.本妥昔单抗维迪昔单抗在复发型霍奇金淋巴瘤和系统性间变性大细胞淋巴瘤中的发现和发展。
Nat Biotechnol. 2012 Jul 10;30(7):631-7. doi: 10.1038/nbt.2289.
9
Induction of DNA strand breaks is critical to predict the cytotoxicity of gemtuzumab ozogamicin against leukemic cells.诱导 DNA 链断裂对于预测吉妥珠单抗奥唑米星对白血病细胞的细胞毒性至关重要。
Cancer Sci. 2012 Sep;103(9):1722-9. doi: 10.1111/j.1349-7006.2012.02343.x. Epub 2012 Jul 11.